Arrowhead Pharmaceuticals (ARWR) Reaches New 52-Week High at $7.18
Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) shares reached a new 52-week high on Monday . The company traded as high as $7.18 and last traded at $7.18, with a volume of 2504970 shares trading hands. The stock had previously closed at $6.66.
A number of research analysts have recently weighed in on ARWR shares. Piper Jaffray Companies raised Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price target on the stock in a research note on Monday, November 27th. BidaskClub raised Arrowhead Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, December 27th. Cantor Fitzgerald set a $2.00 price target on Arrowhead Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, December 12th. ValuEngine raised Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, November 30th. Finally, B. Riley started coverage on Arrowhead Pharmaceuticals in a research note on Friday, January 5th. They issued a “neutral” rating and a $3.00 price target on the stock. Four investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company. Arrowhead Pharmaceuticals has an average rating of “Buy” and an average price target of $4.70.
The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $641.88, a P/E ratio of -15.68 and a beta of 2.40.
In related news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the sale, the chief operating officer now owns 948,356 shares of the company’s stock, valued at approximately $3,499,433.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 4.60% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. Vanguard Capital Wealth Advisors acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $119,000. Macquarie Group Ltd. acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $123,000. Jane Street Group LLC acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $130,000. Two Sigma Investments LP acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $146,000. Finally, Goldman Sachs Group Inc. raised its stake in Arrowhead Pharmaceuticals by 297.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 173,078 shares of the biotechnology company’s stock worth $637,000 after buying an additional 129,488 shares during the period. 26.88% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Arrowhead Pharmaceuticals (ARWR) Reaches New 52-Week High at $7.18” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally stolen and reposted in violation of United States & international copyright laws. The legal version of this story can be accessed at https://www.watchlistnews.com/arrowhead-pharmaceuticals-arwr-reaches-new-52-week-high-at-7-18/1909482.html.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.